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Abstract:  The WU polyomavirus (WUPyV) is a novel member of the family 
Polyomaviridae recently detected in respiratory tract specimens by shotgun sequencing. 
Intriguingly, viral genome has been detected in 0.4% to 11.5% of respiratory tract 
specimens from children with respiratory disease. The levels of co-infection with 
established respiratory viruses were in the range between 30.8% and 91.7%. Moreover, 
some studies report detection of WUPyV in stool or serum. So far, WUPyV infections can 
not be distinguished from other viral infections by means of clinical symptoms. 
Respiratory tract disease like pneumonia or bronchitis is frequently observed in patients 
harbouring WUPyV. Detection of viremia suggests systemic infections. However, the 
available data do not prove WUPyV to be a human pathogen. Further investigations are 
necessary. 
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1. Introduction 
Respiratory tract infections are a major cause of hospital admission in infants and young children. 
They are caused by a broad spectrum of established respiratory tract pathogens, particularly by viruses 
including the respiratory syncytial virus (RSV), the most important cause of severe respiratory tract 
infections in young children, influenza viruses, parainfluenza viruses, rhinoviruses, coronaviruses 
(229E, OC43), and adenoviruses. Studies investigating the entire spectrum of established respiratory 
tract pathogens are rare and mostly based on the detection of pathogen specific antibodies. Only in 
recent years, a few studies became available presenting data based on the direct detection of relevant 
infectious agents. Creer and co-workers [1] identified at least one potential pathogen in 69% of 
specimens from adults suffering from lower respiratory tract infections (LRTI, 63% contained viruses, 
26% contained bacteria) still leaving a significant diagnostic gap to be filled with so far unidentified 
pathogenic microorganisms.  Additional agents associated with respiratory tract infections have been 
discovered recently, e.g. the human metapneumovirus (hMPV) [2], coronaviruses (NL63, HKU1) 
[3,4], and the human bocavirus (HBoV) [5]. Furthermore, herpes viruses may contribute to fill this gap 
as they are assumed to trigger respiratory tract infections [6,7]. Unfortunately, relevant studies did not 
often include them. 
By now, the pathogenic impact of the human metapneumovirus and its relevance on respiratory 
tract infections has been well established.  It is a common cause of upper (URTI) and lower respiratory 
tract infections (LRTI) in children, elderly, and immunocompromised persons; asymptomatic 
infections seem to be uncommon [8]. hMPV has been identified to be an important cause of 
bronchiolitis in young children. The novel human coronavirus HCoV-NL63 is also widely accepted to 
be a significant respiratory tract pathogen. A strong association with croup has been shown [9]. Human 
coronavirus HCoV-HKU1 infections are observed rather infrequent, often in children with underlying 
diseases [4]. Several reports link the virus with pneumonia and bronchiolitis. For the human bocavirus 
(HBoV) an increasing number of reports present evidence for an association with respiratory tract 
infections; however, co-infections with established respiratory tract pathogens are frequent.  
Recently, the WU polyomavirus was detected in respiratory tract specimens [10]. 
2. Discovery of WU Polyomavirus (WUPyV) 
The first polyomaviruses were isolated in 1971 and named JC virus and BK virus. In 2007 and 2008 
3 further viruses of this particular family were described for the first time: WU polyomavirus, KI 
polyomavirus, and Merkel cell polyomavirus [11]. WUPyV was discovered by shot gun sequencing of 
nasopharyngeal aspirate of a three-years-old child from Australia suffering from pneumonia [10]. The 
investigators isolated total nucleic acids from the nasopharyngeal aspirate, randomly amplified 
fragments, and cloned them. Sequences of the obtained clones gained by shot gun sequencing were 
subjected to automated editing and database searches.  
The combination of these technologies led to the identification of a DNA-sequence distant to all 
sequences included in the sequence database, but related to viruses of the family Polyomaviridae. 
Thus, the identification of a novel virus belonging to this viral family has been proposed, exclusively 
based on molecular data. So far, no system for in vitro or in vivo propagation has been discovered, 
neither a cell line nor an animal model. Thus, until now Koch’s postulates could not be fulfilled. Viruses 2009, 1                                       
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However, the molecular data form reasonable evidence to propose the existence of the novel virus 
WUPyV.  
Large-scale screening based technologies as the one used for the discovery of WUPyV may be a 
powerful tool in discovering new infectious agents causing respiratory tract diseases particularly with 
regard to the etiological gap of up to 40%. 
3. Classification of WUPyV 
The novel virus has a 5229 bp dsDNA genome with a GC-content of 39%. The genome contains an 
early coding region encoding the T-antigens, a late coding region encoding structural proteins, and a 
non-coding control region [10]. All features are typical for members of the polyomavirus family. The 
sequence identity of WUPyV at the amino acid level to all of the well-known polyomaviruses ranged 
from 15% - 49%. The closest relative within the virus family is the KI polyomavirus (KIPyV) with a 
sequence identity of 68%, which was described briefly before WUPyV. Thus, both viruses were 
grouped into a new subclass of the polyomavirus family. However, the international committee on 
taxonomy of viruses (ICTV) has not recognised WUPyV or KIPyV yet. 
4. Molecular Features 
Typical members of the family Polyomaviridae form small, non-enveloped, icosahedral particles 
with 40-45 nm in diameter containing a supercoiled dsDNA genome [11]. The virion is made up by 
72 pentamers of the structural protein VP1, each pentamer binds to a single copy of VP2 or VP3. The 
genome is attached to cellular histones. There is no evidence hinting at a virus structure for WUPyV 
differing from other polyomaviruses. However, WUPyV virions have not been displayed by electron 
microscopy, thus there is no evidence for the precise virion structure at this stage. 
Based on the genome organisation, two subclasses of the polyomavirus family have been 
postulated: the primate-like group and the mouse polyoma-like group [10]. The genome of members of 
both subclasses is divided into three regions. The early coding region encodes at least the small T-
antigen and the large T-antigen. Both are binding partners of the RB-protein and p53. The late coding 
region encodes at least the structural proteins VP1-VP3, and the non coding control region contains 
viral promoters and the origin of replication. The early coding region of members of the mouse 
polyoma-like group additionally encodes the medium T-antigen, whereas the late coding region of 
members of the primate-like group additionally encodes the structural protein agnoprotein. Apart from 
KIPyV, the JC virus and the BK virus are the closest relatives of WUPyV based on genome 
organisation and amino acid sequence. The early coding region contains a splice site for the large T-
antigen and binding domains for the RB-protein and p53. However, WUPyV neither encodes open 
reading frames for the middle T-antigen nor the agnoprotein. Thus, WUPyV and KIPyV were 
provisionally grouped into a third subclass of the polyomavirus family. So far, no expression studies 
have been conducted on WUPyV to clarify whether the predicted open reading frames are in fact 
expressed during the viral infection of the target. Interestingly, as shown for HBoV the predicted 
transcripts of a virus are not necessarily identical to the transcripts detectable in an infected cell [12]. 
There is the need for an appropriate experimental system to carry out expression studies on WUPyV 
for further characterization. Viruses 2009, 1                                       
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5. Course of Infection 
Polyomaviruses have a restricted host range. The BK virus and the JC virus, the closest relatives of 
WUPyV within the well established members of the virus family, are human-specific. This suggests a 
host range restricted to humans for WUPyV, too. Infection with BKV takes place in early childhood; 
90% of 5-9 years old children are seropositive. WUPyV infections have been reported predominantly 
in children <3 years of age [10] suggesting a strong increase of seropositivity during early childhood 
for this virus, too. The incubation period of WUPyV infections is unknown. Respiratory transmission 
has been suggested for JC virus and BK virus although the diseases related to these viruses are not 
involving the respiratory tract. Both viruses can be extracted from tonsil tissue [13,14]. The viral entry 
route for WUPyV is not completely defined. It could be defined by uptake through dividing cells of the 
upper respiratory tract and the oropharynx. In this case it would be likely that mostly children are at 
risk of infection as, due to their growing up, their anabolism is enhanced involving increased cell 
division. Alternatively transmission may occur occasionally by blood transfusion and organ 
transplantation. 
JC virus and BK virus primary infections are typically subclinical or linked to mild respiratory 
illness [13,15]. Viral dissemination to the target cells occurs via blood [16]. Sites of lifelong 
persistence are epithelial cells of the kidney for BK virus [17] and lymphocytes, oligodendrocytes as 
well as epithelial cells of kidney for JC virus [18]. 5% of immunocompetent BK virus carriers show 
viruria [19], 20 – 30% show shedding of JC virus [20]. This indicates that viral persistence can be 
terminated and viral reactivation can take place even in immunocompetent persons. Reactivation can 
be assumed to an obviously higher extent in immunocompromised individuals. Concordantly the 
related diseases, hemorrhagic cystitis and polyomavirus nephropathy for BK virus and progressive 
multifocal leukencephalopathy (PML) for JC  virus, predominantly occur in persons with reduced 
immunocompetence. As WUPyV was detected in a respiratory tract specimen the respiratory tract can 
be assumed to be the entry site for this virus, too. The virus was detected in serum indicating that the 
dissemination occurs via blood. So far, sites of persistence have not been identified. The virus has not 
been detected in urine [10]. Thus, epithelial cells of kidney may not be the site of persistence for 
WUPyV.  
WUPyV is made responsible for upper and lower respiratory tract diseases, e.g. bronchiolitis, 
croup, and pneumonia [10]. Besides nasopharyngeal samples, WUPyV could also be detected in stool 
samples [21], even in patients without any apparent clinical respiratory symptoms [22]. However, it 
has to be determined, whether WUPyV is able to replicate in the intestine or whether it accumulates 
there by oral ingestion.  
6. Detection of WUPyV-Infections 
For detection of WUPyV-infections several conventional PCR formats as well as real-time PCR 
protocols were developed reporting sensitivities up to 100% and specificities up to 97.7% [10,23-25]. 
Antigen or antibody detection formats have not been reported, so far. No culture system is known at 
this time. 
The diagnostics of established respiratory viruses is based on a broad spectrum of available assays, 
aiming at the detection of virus-specific antibodies, viral protein, or viral nucleic acids. Acute Viruses 2009, 1                                       
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respiratory tract infections commonly have a short incubation period. Thus, antibodies are usually not 
present at the beginning of the acute phase of the disease. For this reason, detection of virus-specific 
antibodies by complement fixation assays, enzyme linked immunosorbent assays (ELISA), or 
immunofluorescence assays (IFA), all of which are available for established respiratory viruses, is 
inappropriate for the identification of the etiologic agent causing an acute respiratory tract infection, 
but useful for retrospective or epidemiological studies. Direct detection of viral protein or viral nucleic 
acids is the mode of choice for respiratory virus diagnostics. Viral cell culture represents the gold 
standard for the well established respiratory viruses, but is too slow for in time diagnostics. Less time 
consuming methods have been developed. These comprise polymerase chain reaction (PCR), antigen-
specific ELISA, antigen-specific IFA, and, available only for a few respiratory viruses, very fast 
immunochromatographic assays. Sensitivity and specificity of these assays vary considerably. The 
PCR displays the highest sensitivity. Thus, being restricted to PCR formats for detection of WUPyV is 
no bias to sensitivity. Particularly real time PCR formats have an established track record in both, very 
sensitive detection and differentiation between colonisation and acute infection based on the 
quantitative data [26,27]. Availability of automated extraction of nucleic acids permits short 
processing times and, by this, handling of large specimen cohorts [28].  
7. Epidemiology 
Following the discovery of WUPyV in Australia, the virus was detected in specimens from patients 
with respiratory tract disease on all continents suggesting a worldwide distribution [10,29-31]. So far, 
WUPyV-DNA was reported to be found in respiratory tract specimens (e.g. nasopharyngeal washes, 
tracheal secretion, BAL), serum, and faeces. The virus could not be detected in urine or from UV light-
associated primary malignant lymphomas [10,32]. Specimens from other malignant diseases have not 
been investigated. The use of tracheal secretion for diagnostics has been shown to lead to an 
underestimation of the rate of positive specimens compared to other respiratory materials for HBoV 
[33]. This may be true for WUPyV, too.  
The data available are mainly based on retrospective studies exclusively including symptomatic 
patients. The detection rate in respiratory samples from children with respiratory disease varies from 
0.4% to 11.5% [34,35]. The age of WUPyV infected patients ranged from a few weeks to 53 years, 
children <3  years of age were dominating. Infections were predominantly detected in late winter, 
spring, and early summer [36]. High infection rates were reported for study populations preselected for 
lack of immunocompetence. HIV positive patients had detection rates of up to 35.7% in respiratory 
tract specimens and 8.3% in blood [37,38]. The rates of co-infection with established respiratory 
viruses lay between 30.8% and 91.7% [39,40], commonly exceeding 50%. WUPyV was detectable in 
blood, possibly indicating its potential for systemic infections.  
Le and co-workers [41] presented evidence for viral persistence, Wattier et al. [36] for nosocomial 
infections with WUPyV. 
The real time protocols available allow the quantification of WUPyV. Quantification of viral loads 
in respiratory tract specimens revealed viral titers up to 10
10 copies/ml, but low and medium viral loads 
were dominating [21,24]. No correlation between viral load and the rate of co-infection or clinical 
diagnoses was observed.  Viruses 2009, 1                                       
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Few studies included asymptomatic control groups [34,36,42-44]. The results were not concordant 
and reached from higher detection rates in the control group to higher detection rates among the group 
of patients with respiratory tract diseases.  
Prospective studies have been published only recently. Van der Zalm and co-workers [34] reported 
the detection of WUPyV in a cohort of 18 children. Their parents were contacted twice a week over a 
6-months period (November to April) and asked for symptoms of respiratory tract disease in their 
children. Every two weeks respiratory tract specimens were collected, regardless of respiratory 
symptoms. 11.5% of the specimens of children with symptoms were WUPyV positive, but only 3.1% 
of specimens of healthy children, indicating at least an association of WUPyV with disease. 
8. Therapy 
To this time there are no studies available concerning therapeutic interventions. This is mainly due 
to the retrospective nature of most investigations. Further, no causal association between WUPyV and 
respiratory disease has been shown yet [45]. As the need for therapeutics is driven by associating 
infections with disease, studies on therapeutic interventions are not to be expected in the near future. 
For BK virus associated nephropathy in renal transplant patients, reduction of immunosuppressive 
therapy is recommended if possible. In the case of progressive renal dysfunction fluoroquinolones 
(antibacterials), intravenous immunoglobulines, leflunomide, and – in otherwise refractory cases – 
cidofovir could be administered. For JC virus caused progressive multifocal leukoencephalopathy 
(PML) no specific therapy exists. In HIV-positive patients HAART induced improvement of cellular 
function may lead to an at least temporary improvement. Failure of treatment approaches with 
interferon alfa-2b, cytarabine, cidofovir, and topotecan has been documented [46]. 
9. Conclusions 
The discovery of novel respiratory viruses has the potential to diminish the diagnostic gap for 
respiratory tract infections. Creer and co-workers [1], who omitted the recently identified respiratory 
viruses in their study on adults, reported a diagnostic gap of 31%. The share of specimens from 
children negative for any respiratory pathogen investigated was 22% when hMPV, HBoV, and HCoV-
NL63 were included [47]. No study included the novel polyomaviruses or herpes viruses until now. 
Thus, a further reduction of the respiratory tract infections of unknown origin seems reasonable. 
However, a substantial gap is remaining leaving sufficient room for additional respiratory viruses to be 
discovered in the future. 
So far it has not been finally proven, if WUPyV is a real causative agent for respiratory diseases. 
Association of virus detection with previously unexplained respiratory disease led to the tempting idea 
of WUPyV representing a new etiologic agent, particularly in cases where no other respiratory tract 
pathogen could be identified. Furthermore, the association of mouse pneumotropic polyomavirus with 
intestinal pneumonia and significant mortality [48] indicates that polyomaviruses have the capacity to 
be respiratory tract pathogens.  
Many studies correlating the detection of WUPyV with the incidence of respiratory symptoms 
argue for this hypothesis, but it remains difficult to prove as asymptomatic control groups have not 
been investigated sufficiently. Additionally, the studies including control groups report dissenting Viruses 2009, 1                                       
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findings. However, in two studies asymptomatic individuals display a lower frequency of virus 
detection compared to symptomatic patients. One of these is the only prospective study available. 
The difficulty to prove WUPyV to be a respiratory pathogen may be due to the fact that most 
studies available so far try to correlate the virus with respiratory tract disease in general. In case of 
WUPyV being the causative agent of a particular entity of respiratory tract disease, inclusion of 
patients displaying any kind of respiratory disease may bias the investigation. Focussing on a single 
entity of respiratory disease proved successful for HCoV-NL63, which was shown to cause croup. 
No association of WUPyV viral loads and clinical symptoms could be observed so far, and co-
infections with other viruses were described frequently. This weakens the hypothesis of WUPyV being 
a respiratory tract pathogen. However, collection of samples was not performed by means of a 
standardized protocol among the various groups or at a defined time point, after onset of symptoms. As 
viral loads decrease during the acute phase of infection, the combination of longitudinal data from 
different time points in one analysis may bias the correlation of viral loads and symptoms. 
Furthermore, detection of co-infection does not exclude pathogenic potential for WUPyV, as early 
childhood is characterized by subsequent episodes of respiratory infections. Co-detection of the 
declining pathogen responsible for the last episode of respiratory disease and the pathogen responsible 
for the present, acute disease has to be expected. Only determination of the viral load kinetics would 
allow defining the clinical impact of a detectable microorganism. 
The large T-antigen of WUPyV contains binding sites for the RB protein and p53. Thus, 
tumourigenic potential cannot be excluded. However, the association of WUPyV with other diseases, 
particularly tumour diseases has not been sufficiently investigated yet. 
Taken together, the currently available data neither prove nor deny WUPyV to be a respiratory tract 
pathogen. Several scenarios may describe the role of the virus best. WUPyV may be 
(1) part of the endogenous viral flora without pathogenic potential; 
(2) an opportunistic pathogen with pathogenic potential in the respiratory tract under conditions still to 
be defined; 
(3) a pacemaker for secondary infections; 
(4) a viral pathogen using the respiratory tract only as an entry route to reach the final target cell; 
infection of this cell type is the basis of a disease not related to the respiratory tract. 
To reach a final conclusion more powerful, controlled studies need to be performed prospectively. 
However, retrospective analysis of age- and time-matched control populations also permits 
conclusions if the data collected at the time are related to respiratory illness. Ideally, prospective 
studies would be carried out in a multicenter-design including control groups concentrating on the 
correlation of WUPyV with single entities of respiratory tract diseases. Criteria for inclusion of 
specimens have to be comparable, as well as the time point and the protocol for extraction of 
specimens. All known or suspected respiratory tract pathogens should be included and follow-up 
investigations should be performed. The detection method of choice would be quantitative PCR to 
allow discrimination between colonisation and productive infection. Additionally, serological 
investigations should be included to show that the patients seroconvert in response to an infection. The 
study participants should be evaluated before enrolment. Beside investigation of respiratory tract 
disease, the cell type hosting the persisting virus has to be identified and a possible association with 
tumour diseases has to be investigated. Viruses 2009, 1                                       
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